氘可来昔替尼(Deucravacitinib)全网公布的2024年的最新价格

Introduction: Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, but should not be used in patients who have failed to respond to, are intolerant to, or have contraindications to standard systemic therapies (including cyclosporine, methotrexate, and phototherapy).

The latest price of Deucravacitinib in 2024 announced on the entire website

The original drug was developed and produced by Bristol-Myers Squibb Company (BMS) in the United States. It has been launched in China and has been included in medical insurance. The winning price of medical insurance is 995$. The price of the generic version of deuterated colexitinib produced by Ziska Pharmaceutical Factory in Bangladesh is about 550$-850$ per box, and the specification of a box is 6mgx30 tablets.

For reference only, the actual price at the time of purchase may vary due to factors such as drug version, reimbursement ratio, purchase channel, etc. Before taking deuterated colexitinib, understand the drug indications, medications for special groups, etc.

Special population use of Deucravacitinib

1. Pregnant women: It is recommended that women are prohibited from taking Deucravacitinib during pregnancy.

2. Breastfeeding women: There is currently no data on the presence of deuterated colexitinib in human milk; to protect the health of the baby, women should not use deuterated colexitinib during lactation. If they must take this drug, it is recommended to stop breastfeeding.

3. Children: The safety and effectiveness of deuterated colexitinib in pediatric patients have not yet been determined, and its use in children is not recommended.

In patients with mild, moderate, or severe renal impairment, and in patients with end-stage renal disease (ESRD) receiving dialysis, no dosage adjustment of deuterated colexitinib is required.

Precautions for Deucravacitinib

1. During and after treatment with Deucravacitinib, closely monitor the patient for signs and symptoms of infection.

2. Patients who develop new infections during treatment should undergo timely and complete diagnostic testing, initiate appropriate antibacterial treatment and closely monitor the patient.

3. Monitor for viral hepatitis recurrence in accordance with clinical guidelines during treatment with deuterated colexitinib.

4. Regularly assess serum triglycerides during treatment according to clinical guidelines for hyperlipidemia.

Monitor patients for signs and symptoms of active tuberculosis during treatment with colexitinib and assess serum aminotransferase levels during treatment consistent with routine patient management of patients with known or suspected liver disease.